Reclassification of prostate cancer risk using sequentially identified SNPs: Results from the REDUCE trial

Haitao Chen,R. Na,Vignesh T. Packiam,Carly A. Conran,D. Jiang,S. Tao,Hongjie Yu,Xiao-ling Lin,W. Meng,S. Zheng,C. Brendler,B. Helfand,Jianfeng Xu
DOI: https://doi.org/10.1002/pros.23369
2017-07-03
The Prostate
Abstract:Although the clinical validity of risk‐associated single nucleotide polymorphisms (SNPs) for assessment of disease susceptibility has been consistently established, risk reclassification from increasing numbers of implicated risk‐associated SNPs raises concern that it is premature for clinical use. Our objective is to assess the degree and impact of risk reclassification with the increasing number of SNPs.
What problem does this paper attempt to address?